Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer
Colorectal Neoplasm
Explore 117 assets in Colorectal Neoplasm →Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Pfizer
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
36High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00976508CT.gov Figitumumab Combined With Pegvisomant For Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00560560CT.gov Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer (this asset) | Pfizer | P2 | CCC · 51 |
| Oxaliplatin | Peking University Cancer Hospital & Institute | P4 | BBB |
| Fluorouracilum | Rutgers, The State University of New Jersey | P4 | BBB |
| Irinotecan | Shanghai Zhongshan Hospital | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Nottingham University Hospitals NHS Trust | P4 | BBB |
| Regorafenib | Sergey Orlov, MD | P4 | BB |
| Capecitabine | Rutgers, The State University of New Jersey | P4 | BB |
| Nivolumab | Bristol-Myers Squibb | P3 | BB |
| Vandazole | Helsinki University Central Hospital | P4 | BB |
+41 more in the Colorectal Neoplasm cohort
Other indications for Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P2 | CCC · 50 |
| Non-Small Cell Lung Carcinoma | — | P3 | CCC · 50 |
| Lung Large Cell Carcinoma | — | P3 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer in Colorectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g2-anti-human-insulin-like-growth-factor-i-receptor-human-monoclonal-cp-751871-clone-2132-heavy-chain-disulphide-with-human-monoclonal-cp-751871-clone-2132-light-chain-dimer-colorectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →